Form 4: Tvardi Therapeutics Executive Acquires Stock Options Following Merger

Chief Medical Officer John Saewook Kauh M.D. reports acquisition of stock options in Tvardi Therapeutics following a merger.

Summary

• John Saewook Kauh M.D., Chief Medical Officer of Tvardi Therapeutics, reported a transaction on April 15, 2025.
• The transaction involved the acquisition of 74,049 employee stock options with an exercise price of $6.12.
• These options were received in exchange for stock options to acquire 552,129 shares of Legacy Tvardi common stock at $0.82 per share, pursuant to a merger agreement.
• The merger involved CT Convergence Merger Sub, Inc., a subsidiary of Tvardi Therapeutics, and Legacy Tvardi, with Legacy Tvardi surviving as a wholly-owned subsidiary.
• 25% of the shares subject to the option vested on the one-year anniversary of the vesting commencement date, with the remaining shares vesting in 36 equal monthly installments.
• The name of the Issuer was changed from Cara Therapeutics, Inc. to Tvardi Therapeutics, Inc. after the merger.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing related to executive compensation following a merger. It doesn't contain information that would significantly sway investor sentiment positively or negatively.

Industry Context

This filing reflects standard executive compensation practices following a merger, ensuring alignment of management interests with the newly formed company.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.
• The vesting schedule described is typical, with a combination of cliff vesting (25% after one year) and subsequent monthly vesting to encourage long-term commitment.
• Mergers often trigger adjustments to existing equity awards to reflect the new corporate structure and ownership.

Stakeholder Impact

• The stock option grant aligns the Chief Medical Officer's interests with those of the shareholders.
• The merger and subsequent equity adjustments have no immediate impact on customers, suppliers, or creditors.

Key Dates

Keywords

Tvardi Therapeutics, stock options, merger, Form 4, Kauh, Chief Medical Officer, equity, acquisition